DE60336978D1 - Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper - Google Patents

Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper

Info

Publication number
DE60336978D1
DE60336978D1 DE60336978T DE60336978T DE60336978D1 DE 60336978 D1 DE60336978 D1 DE 60336978D1 DE 60336978 T DE60336978 T DE 60336978T DE 60336978 T DE60336978 T DE 60336978T DE 60336978 D1 DE60336978 D1 DE 60336978D1
Authority
DE
Germany
Prior art keywords
hiv
cbd
neutralizing antibodies
epitope
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336978T
Other languages
English (en)
Inventor
Ara Hovanessian
Jean-Paul Briand
Sylviane Muller
Bernard Krust
Josette Svab
Elias Said
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60336978D1 publication Critical patent/DE60336978D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
DE60336978T 2003-04-11 2003-04-11 Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper Expired - Lifetime DE60336978D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03290919.4A EP1466924B9 (de) 2003-04-11 2003-04-11 Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper

Publications (1)

Publication Number Publication Date
DE60336978D1 true DE60336978D1 (de) 2011-06-16

Family

ID=32865088

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336978T Expired - Lifetime DE60336978D1 (de) 2003-04-11 2003-04-11 Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper

Country Status (6)

Country Link
US (2) US7364744B2 (de)
EP (1) EP1466924B9 (de)
AT (1) ATE508139T1 (de)
DE (1) DE60336978D1 (de)
ES (1) ES2366185T3 (de)
HK (1) HK1072264A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007322A (es) 2003-01-06 2006-02-17 Angiochem Inc Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
WO2007039458A2 (en) * 2005-09-21 2007-04-12 Cytos Biotechnology Ag Hiv peptide conjugates and uses thereof
EP2061434A2 (de) * 2006-09-08 2009-05-27 The Regent of the University of California Herstellungsform für polymer-mikro- und nanoteilchen
WO2008046228A1 (en) * 2006-10-19 2008-04-24 Angiochem, Inc. Compounds for stimulating p-glycoprotein function and uses thereof
US20080102073A1 (en) * 2006-10-30 2008-05-01 Wayne Koff Antigen-Antibody Complexes as HIV-1 Vaccines
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2161279A1 (de) * 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Überlappenden neutralisierenden Determinanten entsprechende synthetische Peptide im CBD1-Epitop zum Induzieren von allgemein neutralisierenden Antikörpern
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US10100093B2 (en) * 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
CA3016352A1 (en) * 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
EP3475296A1 (de) * 2016-06-22 2019-05-01 AMSilk GmbH Artikel mit einem seidenpolypeptid zur antigenabgabe
EP3519428A4 (de) 2016-10-03 2020-07-08 Duke University Verfahren zur identifizierung von immunogenen durch targeting unwahrscheinlicher mutationen
CN111281973A (zh) * 2020-03-31 2020-06-16 清华大学 含有trpv2激动剂的疫苗佐剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE86636T1 (de) * 1984-10-18 1993-03-15 Pasteur Institut F antigene vom menschlichen immunodefizienz-virus und deren verwendungen.
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
EP0220273B2 (de) * 1985-04-29 2007-01-17 Bio-Rad Laboratories, Inc. Synthetische antigene zum nachweis von aids
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
JPH01501547A (ja) * 1986-06-12 1989-06-01 バイオジェン　ナームローズ　ベンノットシャップ Ｈｉｖ感染の病因に関するペプチド
US6139843A (en) * 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
EP0708659A4 (de) * 1993-06-07 2000-08-23 Genentech Inc Hiv hüllpolypeptid
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
EP1368478B1 (de) * 2001-01-05 2006-04-26 Sanofi Pasteur Polypeptid, das neutralisierende antikörper gegen hiv induziert

Also Published As

Publication number Publication date
US20100247618A1 (en) 2010-09-30
US8173767B2 (en) 2012-05-08
EP1466924B1 (de) 2011-05-04
ATE508139T1 (de) 2011-05-15
US20050124540A1 (en) 2005-06-09
ES2366185T3 (es) 2011-10-18
US7364744B2 (en) 2008-04-29
EP1466924A1 (de) 2004-10-13
EP1466924B9 (de) 2013-06-19
HK1072264A1 (en) 2005-08-19

Similar Documents

Publication Publication Date Title
ATE508139T1 (de) Synthetische peptid-hiv-vakzine: das cbd-epitop als effizientes immunogen zur induktion hiv- neutralisierender antikörper
Shape Babies Virus Antigenic Relationships
BRPI0509606A (pt) emulsões de óleo-em-água microfluidizadas e composições para vacinas
Nyika et al. DNA vaccination with map1 gene followed by protein boost augments protection against challenge with Cowdria ruminantium, the agent of heartwater
DE60011571D1 (de) Verbindungen mit immunologischem adjuvanseffekt
Vordermeier et al. Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
YU24004A (sh) Interleukin-12 kao adjuvant veterinarske vakcine
Zhang et al. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon
Uren et al. Effective vaccination of cattle using the virion G protein of bovine ephemeral fever virus as an antigen
WO2009105355A3 (en) A novel neospora caninum vaccine
WO2002068654A3 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
MX2010003220A (es) Proteinas inmunogenicas de membrana exterior derivada de genoma de leptospira y composiciones y metodos basados en las mismas.
MXPA05012270A (es) Materiales y metodos para inmunizar en contra de la infeccion por virus de inmunodeficiencia de felino.
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO2008097267A3 (en) Vaccines against vesicular stomatitis
JP2013542942A (ja) 多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原
WO2021202599A3 (en) Adeno-associated virus based compositions and related methods for inducing humoral immunity
US9534020B2 (en) Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide
WO2006091455A3 (en) Molecular scaffolds for hiv-1 immunogens
Peet et al. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV‐1 gp120
CN101628118A (zh) 流感复合多表位dna疫苗及其应用
US20160317648A1 (en) Cap260, cap174 and k0224 hiv-1 envelopes, peptide and compositions
CN107224578B (zh) Hiv疫苗及其制备方法
CN102558314A (zh) 一种hiv免疫原及其制备